JDB-153 Drug Asset Due Diligence Report 2026

This JDB-153 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 11 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 1/2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: HOLD / OPTION

Decision memo

Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.

The central underwriting question is whether JDB-153 can convert its Small molecule drug profile and MNK x VEGFR2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	JDB-153 (query alias: JDB-153)
Modality / target	Small molecule drug; MNK x VEGFR2; MNK inhibitors, VEGFR2 antagonists
Highest global status	Phase 1/2
Originator	Shanghai Jiabao Yaoyin Pharmaceutical Technology Co., Ltd.
Active developers	West China Hospital, Jumbo Drug Bank Co., Ltd

The MCP disease footprint includes Pancreatic Ductal Adenocarcinoma, Hepatocellular Carcinoma, Non-Small Cell Lung Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07175389	Phase 1/2	Not yet recruiting	10	Primary endpoint not disclosed in English source
NCT07075419	Phase 1/2	Not yet recruiting	10	Primary endpoint not disclosed in English source
CTR20241038	Phase 1	Terminated	12	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Evidence gap

The Clinical Trials MCP returned no matched public result record. This is a gating diligence gap, not evidence of failure.

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

JDB-153 addresses Pancreatic Ductal Adenocarcinoma, Hepatocellular Carcinoma, Non-Small Cell Lung Cancer. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 9 matched transaction record(s) under the scope “target-level comparable: MNK x VEGFR2.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: MNK x VEGFR2 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
Not disclosed	Lilly deepens pain strategy with acquisition of MNK inhibitor developer 4E Therapeutics	Preclinical	Financial terms not disclosed
2023-10-24	eFFECTOR Therapeutics to Collaborate with the Northwestern University Division of Hematology and Oncology on an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Acute Myeloid Leukemia	Phase 2	Financial terms not disclosed
2022-05-10	AUM Biosciences Enters into Collaboration with Roche for Clinical Development of AUM001 in Combination with anti-PD-L1 Therapy in Solid Tumor Indications	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Use of pyrrolotriazine compound in preparation of drug for preventing and/or treating fibrosis or related disease thereof”. The milestone feed surfaced a patent-application signal described as “Use of pyrrolotriazine compound in preparation of Anti-tumor drug”. The milestone feed surfaced a patent-application signal described as “Salt form of pyrrolotriazine compound, crystal form thereof, and preparation method therefor”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

HOLD / OPTION